Hamideh Abbaspour Kasgari, H. Samaee, S. A. Samakkhah, Parisa Moradimajd
{"title":"Treatment With Tocilizumab in a Patient With COVID-19","authors":"Hamideh Abbaspour Kasgari, H. Samaee, S. A. Samakkhah, Parisa Moradimajd","doi":"10.18502/PBR.V6I(S2).5662","DOIUrl":null,"url":null,"abstract":"In late December 2019, a global outbreak (pandemic) of the coronavirus was reported, which WHO named 2019-nCoV. The virus is now spreading rapidly and has affected manycountries, including Iran. There is no definitive and effective treatment for this virus yet. This report aimed to define the effect of Tocilizumab in patient with COVID-19. This case report isabout a 52-year-old man with COVID-19 that has been treated with tocilizumab. The reported patient had an acceptable improvement in oxygen saturation but no significant change inlung CT scan. After 3 days treatment patient with Tocilizumab, extensive bilateral lungs involvement still exist but SPO2 level iimprovement up to 90%. According to the results, thisdrug had a positive impact on oxygen saturation. However, we cannot be certain whether this drug positively affected the patient’s coronavirus disease.","PeriodicalId":6323,"journal":{"name":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","volume":"88 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/PBR.V6I(S2).5662","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In late December 2019, a global outbreak (pandemic) of the coronavirus was reported, which WHO named 2019-nCoV. The virus is now spreading rapidly and has affected manycountries, including Iran. There is no definitive and effective treatment for this virus yet. This report aimed to define the effect of Tocilizumab in patient with COVID-19. This case report isabout a 52-year-old man with COVID-19 that has been treated with tocilizumab. The reported patient had an acceptable improvement in oxygen saturation but no significant change inlung CT scan. After 3 days treatment patient with Tocilizumab, extensive bilateral lungs involvement still exist but SPO2 level iimprovement up to 90%. According to the results, thisdrug had a positive impact on oxygen saturation. However, we cannot be certain whether this drug positively affected the patient’s coronavirus disease.